AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8187315
Drug: Both insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both insulin levels
Trial: 2835977
Drug: Diet 1
RxNorm normalized name: Phendiet 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 1 (40% energy as carbohydrate, 10 g dietary fibre)
Trial: 2835977
Drug: Diet 2
RxNorm normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 2 (40% energy as carbohydrate, 52 g dietary fibre)
Trial: 2835977
Drug: Diet 3
RxNorm normalized name: Phendiet 35 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 3 (60% energy as carbohydrate, 84 g dietary fibre)
Trial: 24620666
Drug: Conventional symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional symptomatic treatment
Trial: 31568799
Drug: Oral maribavir
RxNorm normalized name: maribavir
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral maribavir treatment
Trial: 31568799
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of F342Y and H411Y
Trial: 23835011
Drug: Weekly friendly
RxNorm normalized name: Fisherman's Friend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly friendly visits (FV) (n = 7)
Trial: 20655712
Drug: Dendrobium candidum
RxNorm normalized name: Geotrichum candidum
DrugBank: Geotrichum candidum (DB10699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendrobium candidum extract (DCEL) administered orally for 1 week
Trial: 19450062
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 mg/day)
Trial: 19450062
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER (4 mg/day)
Trial: 12740260
Drug: Acetazolamide, 250
RxNorm normalized name: AcetaZOLAMIDE, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide, 250 mg bid
Trial: 12740260
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA), 30 mg bid
Trial: 10850938
Drug: Delayed enteral
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed enteral feeding with immune-enhancing diet (Impact with fiber) administered after gastric ileus resolved
Trial: 27436632
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral and implant)
Trial: 24606117
Drug: Sublingual asenapine
RxNorm normalized name: asenapine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual asenapine 10 mg
Trial: 21960182
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol (0.65 g/kg)
Trial: 18801887
Drug: Adiponectin concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin concentrations (highest quintile > 9.8 microg/mL)
Trial: 16207605
Drug: Sustained-release nitrendipine
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nitrendipine microspheres
Trial: 16207605
Drug: Domestic commercial
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic commercial nitrendipine tablets
Trial: 16207605
Drug: Baypress nitrendipine
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baypress nitrendipine tablets
Trial: 12648592
Drug: Complete surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete surgical staging including bilateral salpingo‐oophorectomy, hysterectomy, omentectomy, and pelvic and para‐aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy
Trial: 12648592
Drug: Cisplatin‐based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin‐based chemotherapy following bilateral salpingo‐oophorectomy, hysterectomy, and omentectomy without lymphadenectomy
Trial: 11872915
Drug: Emergent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergent use of anticoagulants
Trial: 11872915
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin or other rapidly acting anticoagulants
Trial: 7648234
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg nocte
Trial: 7648234
Drug: Bezafibrate Slow
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate Slow Release (SR) 400 mg mane
Trial: 7648234
Drug: Combined bezafibrate
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bezafibrate and simvastatin therapy
Trial: 31024653
Drug: Flipped classroom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flipped classroom curriculum with MKSAP readings and weekly case discussions
Trial: 21769617
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of levobupivacaine twice a day postoperatively via preperitoneal catheter
Trial: 16522909
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 0 mg.kg(‐1).d(‐1)
Trial: 16522909
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 5 mg.kg(‐1).d(‐1)
Trial: 16522909
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 10 mg.kg(‐1).d(‐1)
Trial: 16522909
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 15 mg.kg(‐1).d(‐1)
Trial: 16522909
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 25 mg.kg(‐1).d(‐1)
Trial: 16522909
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 35 mg.kg(‐1).d(‐1)
Trial: 23884718
Drug: 125 mL/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL/h intravenously with limited oral intake
Trial: 23884718
Drug: 250 mL/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL/h intravenously with limited oral intake
Trial: 23884718
Drug: 25 mL/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL/h intravenously with ad libitum oral intake of clear liquids
Trial: 19524265
Drug: Gastrografin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (100 mL administered through a nasogastric tube)
Trial: 16316567
Drug: Ferrous L-threonate
RxNorm normalized name: magnesium L-threonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous L-threonate plus placebo ferrous succinate
Trial: 16316567
Drug: Ferrous succinate
RxNorm normalized name: Ferrous succinate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous succinate plus placebo ferrous L-threonate
Trial: 12032434
Drug: 1-week triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week triple therapy (proton pump inhibitor, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily)
Trial: 12032434
Drug: 10-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day triple therapy (proton pump inhibitor, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily)
Trial: 12032434
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple therapy (proton pump inhibitor, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily)
Trial: 10472211
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution 25 ml kg‐1 infused over 15 min
Trial: 10472211
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution 25 ml kg‐1 infused over 30 min
Trial: 10472211
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution 25 ml kg‐1 infused over 15 min and 30 min
Trial: 30384438
Drug: AboBoNT‐A (Dysport)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AboBoNT‐A (Dysport) injections (400 U) into the adductor muscles
Trial: 22267183
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment (8 weeks)
Trial: 21152458
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (clear liquid diet and 4 L of bowel preparation without additional education)
Trial: 11910715
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (ORS) ad libitum (AL group)
Trial: 11910715
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (ORS) in fractionated doses (FD group)
Trial: 1097866
Drug: Soya bean
RxNorm normalized name: Soya bean oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya bean milk (150 ml second-hourly from 7 a.m. to 11 p.m. daily for two weeks)
Trial: 1097866
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no soya bean milk therapy)
Trial: 31287135
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of medications during pregnancy
Trial: 22084157
Drug: Intraocular lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular lens implant
Trial: 10438343
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir (600 mg 2x/day for 5 days)
Trial: 7006273
Drug: Norephedrine in
RxNorm normalized name: Norephedrine
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norephedrine in combination with oestradiol
Trial: 30988147
Drug: Double-lactam combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-lactam combination therapy (DBL)
Trial: 23503651
Drug: Poor oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor oral hygiene (brushing teeth less than daily)
Trial: 21679925
Drug: Transdiagnostic internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic internet cognitive behavioral therapy (iCBT) program consisting of online educational lessons, homework assignments, weekly contact from a clinical psychologist, access to an online forum, and automated emails.
Trial: 16404361
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg m(‐2) (day 1) (arm A)
Trial: 16404361
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg m(‐2) (day 8) and gemcitabine 1250 mg m(‐2) (days 1,8) (arm B)
Trial: 16404361
Drug: Docetaxel 25
RxNorm normalized name: docetaxel 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 25 mg m(‐2) and gemcitabine 800 mg m(‐2) (both given weekly (days 1,8,15)) (arm C)
Trial: 16404361
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 7 followed by docetaxel-based therapy
Trial: 7793191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Atracurium and Vecuronium (cAV)
Trial: 31508730
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (2 hours)
Trial: 28459941
Drug: iddEPC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iddEPC regimen (E 150 mg/m2, P 225 mg/m2, C 2500 mg/m2, reduced to 2000 mg/m2 after 1200 patients) q2w i.v.
Trial: 28459941
Drug: ddEC-PwX regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ddEC-PwX regimen (E 112.5 mg/m2 + C 600 mg/m2 i.v. q2w for 4 cycles, followed by Pw 67.5 mg/m2 i.v. q8d for 10 weeks + X 2000 mg/m2 p.o. days 1-14, q22 for 4 cycles)
Trial: 24355670
Drug: Daily Challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Challenge (multimodal e-mail, web, and mobile-based intervention)
Trial: 24355670
Drug: Traditional weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Traditional weekly health newsletter (control)
Trial: 20518171
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) combined with auricular acupoint sticking (AAS), treated once each day for 15 days, with 3 courses of treatment evaluated after 45 days.
Trial: 17335683
Drug: Treatment algorithms
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment algorithms based on published data and clinical experience
Trial: 2105673
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg naltrexone
Trial: 7262174
Drug: Commercial capsule
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial capsule containing 50 mg of ketoprofen
Trial: 7262174
Drug: Simple capsule
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simple capsule containing 50 mg of ketoprofen
Trial: 7262174
Drug: Commercial capsule
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial capsule taken 6 hourly for thirteen doses
Trial: 7674700
Drug: Ketoprofen solution
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen solution
Trial: 7262174
Drug: Commercial capsule
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial capsule
Trial: 7262174
Drug: Simple capsule
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simple capsule
Trial: 19652072
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/d (AM dosing)
Trial: 19652072
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/d (PM dosing)
Trial: 8653998
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (2 or 10 MU/m2/day SQ for 3 days) concurrent with etoposide
Trial: 8653998
Drug: Etoposide (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (75, 100, or 125 mg/m2/day)
Trial: 6299093
Drug: m-AMSA 120
RxNorm normalized name: m-AMSA
DrugBank: Amsacrine (DB00276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-AMSA 120 mg/m2 intravenously every 3 weeks
Trial: 6299093
Drug: neocarzinostatin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neocarzinostatin 2.0 mg/m2 intravenously daily X 5 every 4 weeks
Trial: 30829505
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy integrated with motivational interviewing
Trial: 17171458
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral day treatment plus housing contingent on drug abstinence
Trial: 17171458
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral day treatment plus housing not contingent on abstinence
Trial: 17171458
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral day treatment plus no housing
Trial: 15080765
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine solution 32 mg
Trial: 15080765
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine tablet 16 mg
Trial: 15080765
Drug: Sublingual buprenorphine/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine/naloxone tablet 16/4 mg
Trial: 15080765
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine solution (all doses)
Trial: 15080765
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine 16 mg tablet with naloxone
Trial: 11220254
Drug: Esmolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (2 mg/kg)
Trial: 9685762
Drug: 0.05 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 percent sodium fluoride and 0.12 percent chlorhexidine rinses, daily from the end of the sixth month of pregnancy until delivery
Trial: 7988301
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg M1 intravenously
Trial: 7988301
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg M2 intravenously
Trial: 7988301
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg glibenclamide (Gb) intravenously
Trial: 7988301
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg glibenclamide (Gb) orally
Trial: 3058290
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean daily dose 3.34 mg)
Trial: 3058290
Drug: Desipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (mean daily dose 192 mg)
Trial: 29174961
Drug: Butorphanol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (0.4 mg kg−1)
Trial: 29174961
Drug: Methadone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.3 mg kg−1)
Trial: 23841572
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (staest) - 3.0 g of plant stanols/d
Trial: 17679633
Drug: Problem-solving treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving treatment (n = 105)
Trial: 15086170
Drug: Polidocanol injection
RxNorm normalized name: polidocanol Injection
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polidocanol injection therapy
Trial: 12438291
Drug: Darusentan 30
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 30 mg/d
Trial: 12438291
Drug: Darusentan 100
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 100 mg/d
Trial: 12438291
Drug: Darusentan 300
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 300 mg/d
Trial: 7574459
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon beta‐1b (alternate-day injections)
Trial: 6990950
Drug: Fentanyl 0.125
RxNorm normalized name: bupivacaine-fentanyl 0.125%-2 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.125 mg
Trial: 30805949
Drug: NGM282 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGM282 3 mg
Trial: 19692630
Drug: Metformin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2000 mg daily, step-up fashion for 8 weeks)
Trial: 19692630
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin administration during clamp
Trial: 17302186
Drug: Antisymptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisymptomatic treatment alone
Trial: 11133370
Drug: efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz (600 mg every 24 h) plus indinavir (1000 mg every 8 h)
Trial: 11133370
Drug: placebo (every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (every 24 h) plus indinavir (800 mg every 8 h)
Trial: 8117053
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg + Hydrochlorothiazide 12.5 mg (L/HCTZ)
Trial: 8117053
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg + Hydrochlorothiazide 25 mg (C/HCTZ)
Trial: 2942416
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg ipratropium powder
Trial: 2942416
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ipratropium powder